Hypoglycemia Risk With SGLT2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists Versus Sulfonylureas Among Medicare Insured Adults With CKD in the United States

Autor: Zhao, Julie Z., Weinhandl, Eric D., Carlson, Angeline M., St. Peter, Wendy L.

Publikováno v: In Kidney Medicine August 2022 4(8)

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Disparities in SGLT2 Inhibitor or Glucagon-Like Peptide 1 Receptor Agonist Initiation Among Medicare-Insured Adults With CKD in the United States.

Autor: Zhao JZ; Department of Pharmaceutical Care & Health Systems, College of Pharmacy, University of Minnesota, Minneapolis, MN.; Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, MN., Weinhandl ED; Department of Pharmaceutical Care & Health Systems, College of Pharmacy, University of Minnesota, Minneapolis, MN.; Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, MN., Carlson AM; Department of Pharmaceutical Care & Health Systems, College of Pharmacy, University of Minnesota, Minneapolis, MN., St Peter WL; Department of Pharmaceutical Care & Health Systems, College of Pharmacy, University of Minnesota, Minneapolis, MN.; Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, MN.

Publikováno v: Kidney medicine [Kidney Med] 2022 Oct 31; Vol. 5 (1), pp. 100564. Date of Electronic Publication: 2022 Oct 31 (Print Publication: 2023).